Education
About Us
Working with TipRanks
Follow Us
vTv Therapeutics (VTVT)
NASDAQ:VTVT
Total Valuation
vTv Therapeutics has a market cap or net worth of $63.44M. The enterprise value is $56.43M.
Market Cap$63.44M
Enterprise Value$56.43M
Share Statistics
vTv Therapeutics has 2,612,257 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,612,257
Owned by Insiders19.44%
Owned by Institutions11.64%
Financial Efficiency
vTv Therapeutics’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -73.14%.
Return on Equity (ROE)-1.51
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-73.14%
Return on Capital Employed (ROCE)-0.73
Revenue Per Employee44.22K
Profits Per Employee-987.17K
Employee Count23
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of vTv Therapeutics is -4.32. vTv Therapeutics’s PEG ratio is 0.06.
PE Ratio-4.32
PS Ratio53.08
PB Ratio6.53
Price to Fair Value6.53
Price to FCF-3.15
Price to Operating Cash Flow-3.15
PEG Ratio0.06
Income Statement
In the last 12 months, vTv Therapeutics had revenue of 1.02M and earned -18.46M in profits. Earnings per share was -3.20.
Revenue1.02M
Gross Profit1.02M
Operating Income-24.18M
Pretax Income-18.36M
Net Income-18.46M
EBITDA-22.52M
Earnings Per Share (EPS)-3.20
Cash Flow
In the last 12 months, operating cash flow was -25.31M and capital expenditures 0.00, giving a free cash flow of -25.31M billion.
Operating Cash Flow-25.31M
Free Cash Flow-25.31M
Free Cash Flow per Share-9.69
Dividends & Yields
vTv Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.87
52-Week Price Change-19.41%
50-Day Moving Average18.08
200-Day Moving Average16.12
Relative Strength Index (RSI)59.51
Average Volume (3m)34.71K
Important Dates
vTv Therapeutics upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
vTv Therapeutics as a current ratio of 7.34, with Debt / Equity ratio of 1.39%
Current Ratio7.34
Quick Ratio7.34
Debt to Market Cap<0.01
Net Debt to EBITDA1.62
Interest Coverage Ratio0.00
Taxes
In the past 12 months, vTv Therapeutics has paid 100.00K in taxes.
Income Tax100.00K
Effective Tax Rate>-0.01
Enterprise Valuation
vTv Therapeutics EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -1.70.
EV to Sales42.40
EV to EBITDA-1.92
EV to Free Cash Flow-1.70
EV to Operating Cash Flow-1.70
Balance Sheet
vTv Therapeutics has $36.75M in cash and marketable securities with $36.17M in debt, giving a net cash position of -$36.58M billion.
Cash & Marketable Securities$36.75M
Total Debt$36.17M
Net Cash-$36.58M
Net Cash Per Share-$14.00
Tangible Book Value Per Share$2.48
Margins
Gross margin is 95.58%, with operating margin of -2377.58%, and net profit margin of -1815.34%.
Gross Margin95.58%
Operating Margin-2377.58%
Pretax Margin-1805.51%
Net Profit Margin-1815.34%
EBITDA Margin-2213.96%
EBIT Margin-2222.71%
Analyst Forecast
The average price target for vTv Therapeutics is $35.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$35.50
Price Target Upside72.75% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast65.54%